Variability of response to anti-thrombotic drug - Analysis of profile of coagulation and fibrinolysis in patients receiving total hip replacement (THR)
Not Applicable
- Conditions
- osteoarthritis of the hip, hip fracture
- Registration Number
- JPRN-UMIN000006337
- Lead Sponsor
- Keio University, School of Medicine, Research Park 5S9
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) patients without consent 2) AST > or = 3 x upper limit or ALT > or = 3 x upper 3) serum CRTNN > 2 mg/dl 4) Hb = or < 10 g/dl, or platelet = or < 100k 5) drug allergy to anticoagulants 6) patients with malignancy under treatment or planning to start treatment within one year 7) primary physician thinks it is inappropriate to enroll the patient
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method plasma concentrations of markers of coagulation and fibrinolysis at the time-point of three weeks after THR
- Secondary Outcome Measures
Name Time Method occurrence of symptomatic VTE, clinically proven bleeding symptom (TIMI major or minor), plasma concentrations of markers of coagulation and fibrinolysis at the time-point of first visiting after discharge